Evidence map›Paper›PMID 27544489›Full record

SynthesisJournal of the American Academy of Dermatology2016

Persistence of atopic dermatitis (AD): A systematic review and meta-analysis.

Jooho P Kim, Lucy X Chao, Eric L Simpson, Jonathan I Silverberg

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Academy of Dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 6 pooled it
28.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 6 syntheses or guidelines pooled it, 265 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health technology assessment (Winchester, England) · 2024
    Trial
  8. Trial
  9. 'High dose' vs. 'medium dose' UVA1 phototherapy in italian patients with severe atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019
    Trial
  10. Trial
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  17. Article
  18. Review
  19. Observational
  20. Observational

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jooho P KimDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Lucy X ChaoDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Eric L SimpsonDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon.
Jonathan I SilverbergDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Northwestern Medicine Multidisciplinary Eczema Center, Chicago, Illinois. Electronic address: JonathanISilverberg@Gmail.com.
Northwestern University · USOregon Health & Science University · US

Funding

Northwestern University Patient-centered Intervention and Engagement TrainingK12HS023011 · AHRQ · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CELLA, DAVID · 2014 to 2018
$3.7M
AHRQ HHS K12 HS023011Medical Research Council MC_PC_15018Wellcome Trust 102215
6 · The paper itself

Abstract

backgroundPrevious studies found conflicting results about whether childhood atopic dermatitis (AD) persists into adulthood.

objectiveWe sought to determine persistence rates and clinical factors associated with prolonged AD.

methodsA systematic review was performed in MEDLINE, EMBASE, Scopus, GREAT, LILACS, Web of Science, Academic Search Complete, and Cochrane Library. Meta-analysis was performed using Kaplan-Meier plots and random-effects proportional hazards regression.

resultsIn total, 45 studies including 110,651 subjects spanning 434,992 patient-years from 15 countries were included. In pooled analysis, 80% of childhood AD did not persist by 8 years and less than 5% persisted by 20 years after diagnosis (mean ± SE: 6.1 ± 0.02 years). Children with AD that persisted already for more than 10 years (8.3 ± 0.08 years) had longer persistence than those with 3 (3.2 ± 0.02 years) or 5 (6.8 ± 0.06 years) years of persistence. Children who developed AD by age 2 years had less persistent disease (P < .0001). Persistence was greater in studies using patient-/caregiver-assessed versus physician-assessed outcomes, female versus male patients (P ≤ .0006), but not in those with sensitivity to allergens (P = .90). Three studies found prolonged persistence with more severe AD. LIMITATIONS: Some studies did not capture recurrences later in life.

conclusionsMost childhood AD remitted by adulthood. However, children with already persistent disease, later onset, and/or more severe disease have increased persistence.

Indexed as

AdolescentAdultAge FactorsAge of OnsetAllergensChildChild, PreschoolDermatitis, AtopicFemaleHumansKaplan-Meier EstimateMalePatch TestsPrognosisProportional Hazards ModelsRecurrenceAllergensatopic dermatitiseczemaepidemiologypersistenceprognosis

Identifiers

PMID27544489
PMCPMC5216177
OpenAlexW2513454888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.